Conference Home

Scientific Agenda

Accommodations & Travel

Sponsorship


Best of Oncology West 2019

OncologyEducation.com is proud to present The Best of Oncology West 2019 Conference. This meeting will highlight the most clinically relevant achievements of 2018 for several different tumour sites, and the faculty will be drawn from some of the most influential oncologists across the globe. 


Learning Objectives:

 • To discuss the pivotal oncology trials presented in the different disease sites

 • To review the current standard of care for key malignancies

 • To discuss the current controversies in the management of specific cancers 


FEES

 

EARLY

*Ends December 20, 2018

REGULAR

Physicians

$160

$210

Nurses/Pharmacists/Allied Healthcare Providers

$80

$120

Residents/Students

$25

$25


 

 

ABOUT THE CHAIRS

DR. SHARLENE GILL, BSC (PHARM), MD, MPH, FACP, FRCPC

Dr. Gill is a Professor of Medicine at the University of British Columbia and Staff Oncologist at the BC Cancer Agency.

Dr. Sharlene Gill is a medical oncologist specializing in gastrointestinal (GI) malignancies. She received a Bachelor’s of Science in Pharmacy (Honors) and an MD (Doctor of Medicine) from the University of British Columbia in 1996 followed by residencies in Internal Medicine and Medical Oncology. Dr. Gill subsequently completed a fellowship in Gl Oncology at the Mayo Clinic (Rochester, MN) and a Master’s of Public Health from the Harvard School of Public Health (Boston, MA) before returning to Vancouver, Canada where she is presently a Professor of Medicine at the University of British Columbia and staff oncologist at the BC Cancer Agency.

Dr. Gill’s areas of expertise are colorectal, pancreatic and hepatobiliary cancers. In addition to her clinical work, she is actively engaged in education and research, with over 80 peer-reviewed publications and book chapters to her credit. She is currently an MBA Candidate at Kenan-Flagler Business School (University of North Carolina, Class of 2017).

Areas of specialization: GI cancers, development of novel therapies, medical education

 

DR. ANIL ABRAHAM JOY, MD, FRCPC

Dr. Joy currently serves as a Professor of Oncology. Division of Medical Oncology, Faculty of Medicine and Dentistry at the University of Alberta and also as a staff Medical Oncologist at the Cross Cancer Institute in Edmonton, Alberta.

Dr. Joy currently serves as a Professor of Oncology. Division of Medical Oncology, Faculty of Medicine and Dentistry at the University of Alberta and also as a staff Medical Oncologist at the Cross Cancer Institute in Edmonton, Alberta.
 
He received his Bachelor of Science Degree (Honours with Distinction, Specialization in Pharmacology) and Medical Doctorate (Honours with Distinction) from the University of Alberta.  He is certified by the Royal College of Physicians and Surgeons of Canada as a specialist in Internal Medicine with subspecialty certification in Medical Oncology.  
His primary oncologic care interests include Breast and Thoracic Malignancies. He is actively involved in patient care, clinical research, medical education, cancer survivorship/well-being, cancer advocacy and global/regional oncology disparity issues and has multiple peer-reviewed publications in these areas.
He is actively involved with the Canadian Clinical Trials Group, and serves as National Chair for the CCTG MA.38 metastatic breast cancer clinical trial.

His former appointments include serving on the Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer, past Chair of the Northern Alberta Breast Cancer Program, Medical Director (Edmonton) of the Alberta Cancer Research Biobank (former CBCF Tumor Bank), pan-Canadian Working Group on Primary Care and Oncology Care Integration (Canadian Partnership Against Cancer) as well as Provincial Chair of the Alberta Breast Cancer Program. He currently serves on the pan-Canadian Oncology Drug Review (pCODR) Canadian Agency for Drugs and Technologies in Health (CADTH) on the Expert Review Committee (pERC) where they assess the clinical evidence and cost-effectiveness of cancer drugs in order to make recommendations to help guide drug funding decisions across Canada.


 

Oncology Clinical News

Powered by OBR Oncology